FY25 consensus $5.14. Abbott (ABT) reaffirms previously provided full-year 2025 organic sales growth guidance of 7.5% to 8.0%, excluding COVID-19 testing-related sales, or 6.0% to 7.0%, when including COVID-19 testing-related sales. Abbott also reaffirms the midpoint of the previously provided full-year 2025 adjusted diluted EPS guidance range and narrows the range to $5.12 to $5.18, which reflects double-digit growth at the midpoint.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Options Volatility and Implied Earnings Moves Today, October 15, 2025
- Notable companies reporting before tomorrow’s open
- Options Volatility and Implied Earnings Moves This Week, October 14 – October 17, 2025
- ABT Earnings this Week: How Will it Perform?
- Align downgraded, NetEase upgraded: Wall Street’s top analyst calls